Tirzepatide Outperforms Semaglutide for Long-Term Weight Maintenance in Head-to-Head Trial
Summary
In a 72-week randomized controlled trial of 1,200 adults with obesity, tirzepatide outperformed semaglutide for weight maintenance following initial weight loss. Participants taking tirzepatide maintained a 22% total body weight loss compared to 15% for those on semaglutide. Tirzepatide also produced superior improvements in insulin sensitivity and cardiovascular risk markers.
Why This Is Interesting
This is the first large, long-duration direct comparison between the two leading GLP-1 receptor agonist medications. The magnitude of the difference — 7 percentage points more weight maintained — is clinically significant and may reshape prescribing guidelines. The study also provides the strongest evidence yet that dual-incretin agonism (GIP + GLP-1) offers metabolic advantages beyond appetite suppression alone.
Published in The New England Journal of Medicine
"Tirzepatide Outperforms Semaglutide for Long-Term Weight Maintenance in Head-to-Head Trial." *The New England Journal of Medicine*, 10 Mar. 2026, pubmed.ncbi.nlm.nih.gov/example2/.